Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Extended Treatment for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 223
- Registration Number
- NCT01330043
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Concurrent Bupropion / Varenicline for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 702
- Registration Number
- NCT01303861
- Locations
- 🇺🇸
Duke Center for Nicotine and Smoking Cessation Research, Winston-Salem, North Carolina, United States
Symptom Burden in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01219673
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Varenicline and Smoking Cessation in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 24
- Registration Number
- NCT01111149
- Locations
- 🇺🇸
University of Minnesota, University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01048983
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 8
- Registration Number
- NCT01046214
- Locations
- 🇺🇸
California Clinical Trials, Glendale, California, United States
Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 893
- Registration Number
- NCT01023659
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
STOP Study: Effectiveness of Zyban in a Clinical Population
- Conditions
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 454
- Registration Number
- NCT01015170
- Locations
- 🇨🇦
West Durham Family Health Team, Pickering, Ontario, Canada
🇨🇦Aberdeen Downtown Nurse Practitioner Clinic, Brantford, Ontario, Canada
🇨🇦Summerville Family Health Team, Mississauga, Ontario, Canada
Combining Varenicline and Bupropion for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 641
- Registration Number
- NCT00943618
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Bupropion for ADHD in Adolescents With Substance Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 105
- Registration Number
- NCT00936299
- Locations
- 🇺🇸
University of Colorado Denver, Adolescent Clinical Research, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.